Diethylpropion and mazindol: An end to the discussion?

Lucchetta, RC; Riveros, BS; Pontarolo, R; Radominski, RB; Otuki, MF; Fernandez-Llimos, F; Correr, CJ

Diethylpropion and mazindol: An end to the discussion?

Lucchetta, RC Riveros, BS Pontarolo, R Radominski, RB Otuki, MF Fernandez-Llimos, F

Correr, CJ

Permalink

Publication Type:: Journal Article
Citation:: Revista da Associacao Medica Brasileira, 2017, 63 (3), pp. 203 - 206
Issue Date:: 2017-03-01

Closed Access

	Filename	Description	Size
	0104-4230-ramb-63-03-0203.pdf	Published Version	99.41 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Lucchetta, RC	en_US
dc.contributor.author	Riveros, BS	en_US
dc.contributor.author	Pontarolo, R	en_US
dc.contributor.author	Radominski, RB	en_US
dc.contributor.author	Otuki, MF	en_US
dc.contributor.author	Fernandez-Llimos, F https://orcid.org/0000-0002-8529-9595	en_US
dc.contributor.author	Correr, CJ	en_US
dc.date.available	2016-08-06	en_US
dc.date.issued	2017-03-01	en_US
dc.identifier.citation	Revista da Associacao Medica Brasileira, 2017, 63 (3), pp. 203 - 206	en_US
dc.identifier.issn	0104-4230	en_US
dc.identifier.uri	http://hdl.handle.net/10453/124363
dc.description.abstract	Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Agência Nacional de Vigilância Sanitáia) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.	en_US
dc.relation.ispartof	Revista da Associacao Medica Brasileira	en_US
dc.relation.isbasedon	10.1590/1806-9282.63.03.203	en_US
dc.subject.classification	General & Internal Medicine	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Obesity	en_US
dc.subject.mesh	Diethylpropion	en_US
dc.subject.mesh	Amphetamines	en_US
dc.subject.mesh	Cyclobutanes	en_US
dc.subject.mesh	Mazindol	en_US
dc.subject.mesh	Appetite Depressants	en_US
dc.subject.mesh	Treatment Outcome	en_US
dc.subject.mesh	Risk Assessment	en_US
dc.subject.mesh	Drug Approval	en_US
dc.subject.mesh	Brazil	en_US
dc.title	Diethylpropion and mazindol: An end to the discussion?	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	63	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	closed_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	63	en_US

Abstract:

Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Agência Nacional de Vigilância Sanitáia) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/124363